Aro Biotherapeutics Secures $41.5M Series B Financing
Funds will support progression of Aro’s pipeline of Centyrin-siRNA programs, including ABX1100, a novel potential treatment for Pompe Disease. Christopher Picariello, President, Johnson & Johnson Innovation – JJDC, Inc. named to Board of Directors. Aro Biotherapeutics, a clinical stage biotechnology company pioneering the development of tissue-targeted genetic medicines, announced it......